List of Lokelma drug patents

Lokelma is owned by Astrazeneca.

Lokelma contains Sodium Zirconium Cyclosilicate.

Lokelma has a total of 13 drug patents out of which 0 drug patents have expired.

Lokelma was authorised for market use on 18 May, 2018.

Lokelma is available in for suspension;oral dosage forms.

Lokelma can be used as treatment of hyperkalemia in adults.

Drug patent challenges can be filed against Lokelma from May, 2022.

The generics of Lokelma are possible to be released after 14 October, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic